These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29471699)

  • 1. Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential.
    Tapia Rico G; Price TJ
    Expert Opin Biol Ther; 2018 Apr; 18(4):449-457. PubMed ID: 29471699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects and progress of atezolizumab in non-small cell lung cancer.
    Vansteenkiste J; Wauters E; Park K; Rittmeyer A; Sandler A; Spira A
    Expert Opin Biol Ther; 2017 Jun; 17(6):781-789. PubMed ID: 28335643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for colorectal cancer: where are we heading?
    Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
    Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
    Morse MA; Hochster H; Benson A
    Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
    Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
    Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
    Krishnamurthy A; Jimeno A
    Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
    Patel R; Bock M; Polotti CF; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Product review on the Anti-PD-L1 antibody atezolizumab.
    Shah NJ; Kelly WJ; Liu SV; Choquette K; Spira A
    Hum Vaccin Immunother; 2018 Feb; 14(2):269-276. PubMed ID: 29194007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab for the treatment of triple-negative breast cancer.
    Heimes AS; Schmidt M
    Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
    Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):28-33. PubMed ID: 28105616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEDI 4736 (durvalumab) in non-small cell lung cancer.
    Jeanson A; Barlesi F
    Expert Opin Biol Ther; 2017 Oct; 17(10):1317-1323. PubMed ID: 28705024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab for treating non-small cell lung cancer.
    Guibert N; Mazières J
    Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
    Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
    Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab for the treatment of bladder cancer.
    Hakenberg OW
    Expert Opin Biol Ther; 2017 Oct; 17(10):1309-1315. PubMed ID: 28737430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.